利拉鲁肽的药理及临床研究进展  

Progress in pharmacological and clinical studies of liraglutide

作　　者：杜燕京[1] 封宇飞[1] 傅得兴[1] 

机构地区：[1]卫生部北京医院药学部,北京100730

出　　处：《中国新药杂志》2010年第23期2115-2119,2123,共6页Chinese Journal of New Drugs

摘　　要：利拉鲁肽是一种酰化胰高血糖素样肽-1(GLP-1)类似物,通过激活GLP-1受体,以葡萄糖依赖性刺激胰岛素分泌并抑制胰高血糖素分泌,临床用于2型糖尿病的二线治疗,可与其他口服降糖药联合使用,但不用于1型糖尿病的治疗。文中通过Medline对利拉鲁肽进行文献检索,并对其药理作用、药动学、临床研究、安全性和药物相互作用等进行综述。Liraglutide is an analogue of acylated glucagon-like peptide-1（GLP-1）.It can stimulate glucose-dependent insulin secretion and inhibit glucagon secretion by activating the GLP-1 receptor.Generally,liraglutide is used for second-line treatment of type 2 diabetes and can be combined with other oral hypoglycemic agents,but not used in the treatment of type 1 diabetes.A literature search was conducted using Medline with the key word liraglutide.The pharmacological effects,pharmackinetics,clinical research,safety and drug interactions of liraglutide were reviewed in this paper.

关 键 词：利拉鲁肽 胰高血糖素样肽-1类似物 2型糖尿病 

分 类 号：R977.15[医药卫生—药品]